Modern Virology Assays for Antiviral Drug Discovery, Vaccine Development and Pathogenesis Investigation

In the past few years, Nexcelom Bioscience has worked with leading labs in the field of virology from government agencies, academic labs, and pharmaceutical companies such as the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID).

These labs have developed modern virology assays utilizing plate imagers to increase sensitivity, efficiency, and accuracy which has led to a reduction of materials used and reduction in time to answer critical questions.

Image Cytometry Assays to Speed up Virology Research

  • Perform microneutralization assays by detecting single-infected cells in 384- and 96-well plates
  • Automated viral infectivity/titer assays based on plaque, fluorescence foci and single infected cells in 24-, 96- and 384-well plates
  • Morphological quantification of plagues/foci in 24- and 96-wells within 5 minutes per plate
  • EC50 & CC50 for antiviral potency and cytotoxicity in the same 384-well plate
  • Cell-based antibody binding inhibition assays in 96-well plates in ~15 minutes for 3 FL colors
  • Automated label-free CPE using bright field imaging in 96-well plates in less than 5 minutes

Faster Answers with a High-throughput cell counter

  • PBMC, whole blood nucleated cell count, and viability for 24 samples in less than 3 minutes

Speed up preclinical mouse model experiments

Immunogenicity testing in mouse and other small animal models are essential for vaccine development. Neutralizing antibody titer measurements are required for many animals at multiple time points. For each small animal, the amount of serum is limited. (Typical mouse blood drawn is less than 200 µl.)

Speed up preclinical mouse model experiments

Micro-Neutralization Assay

It is advantageous to develop micro-neutralization assays in 96-well, or even 384 well format, using an image cytometer such as the Celigo Image Cytometer.

Cellular Immune Analysis

To perform cellular immune analysis, obtaining viable cell count is required. Lower viability samples are typically excluded from high dimension polychromatic flow cytometry measurement.

Using a high-speed, high-throughput cell counter will increase sample processing speed, reduce delay time, and sample degradation.

high-throughput high-speed cell counter

Cellaca MX High Speed, High-throughput Cell Counter

Speed up infectivity / viral titer / microneutralization experiments

Infectivity is a key measurement in all areas of the countermeasure development against any pathogen. This includes antiviral small molecule screens, monoclonal antibody screens, preclinical animal models, pathogenesis, pathway discovery, and vaccine candidate evaluation.

Virus quantification involves in the determining of the number of viral particles in a specific volume to obtain viral concentration.

The infectious viral concentrations are determined using two different approaches.

  1. Apply a serially diluted viral sample to a healthy monolayer of permissive cells and enumerate the number of discretely infected areas originated by each round of infection (Plaque forming assay)
  2. Apply a serial diluted viral sample to a healthy monolayer of permissive cells and document the viral dosage at which 50% cells are killed by the virus (TCID50)

For the first approach in infectious viral titer determination, the traditional manual-based visual plaque counting assays have been consciously improved upon to reduce assay turn-around time, reduce variability introduced by operators, and increase sample throughput.

The Celigo Image Cytometer has been adapted to automate many versions of the counting-based infectivity assays in 384, 96, 48, 24, 12 and 6 well plates.

  • High-content, single infected cell-based infectivity assay
  • Immunofluorescence-based foci formation assay
  • Immuno HRP-based foci formation assay
  • Fluorescent pseudo virus infectivity assays
  • Traditional lytic plaque assays
areas of viral infection

Learn more:

Publications using Nexcelom Image Cytometers in Virology Research, Vaccine Development and Analytical Assay Development for Gene Therapy

Many leading virology labs have utilized Celigo imager and other Nexcelom image cytometer systems in their work. The following are some examples.

Research Areas Viruses

Pathogenesis – Dynamics of virus and human cell interaction during infection

Identify cellular receptor-dependent entry pathway of virus infection

“CD46 facilitates entry and dissemination of human cytomegalovirus”
Stein, K.R., Gardner, T.J., Hernandez, R.E. et al. CD46 facilitates entry and dissemination of human cytomegalovirus. Nat Commun 10, 2699 (2019). https://doi.org/10.1038/s41467-019-10587-1

Human cytomegalovirus (CMV)
Identify genes with antiviral activity against positive-strand RNA viruses

“A Short Hairpin RNA Screen of Interferon-Stimulated Genes Identifies a Novel Negative Regulator of the Cellular Antiviral Response”
Jianqing Li, Steve C. Ding, Hyelim Cho, Brian C. Chung, Michael Gale Jr., Sumit K. Chanda, Michael S. Diamond
mBio Jun 2013, 4 (3) e00385-13; DOI: 10.1128/mBio.00385-13

West Nile virus (WNV)
Key factor (IL-6) in viral clearance, immune cell response, lung repair

“IL-6 ameliorates acute lung injury in influenza virus infection”
Yang, M., Wang, C., Yang, S. et al. IL-6 ameliorates acute lung injury in influenza virus infection. Sci Rep 7, 43829 (2017). https://doi.org/10.1038/srep43829

Innate Immune Response to Influenza Virus at Single-Cell Resolution in Human Epithelial Cells Revealed Paracrine Induction of Interferon Lambda 1
Irene Ramos, Gregory Smith, Frederique Ruf-Zamojski, Carles Martínez-Romero, Miguel Fribourg, Edwin A. Carbajal, Boris M. Hartmann, Venugopalan D. Nair, Nada Marjanovic, Paula L. Monteagudo, Veronica A. DeJesus, Tinaye Mutetwa, Michel Zamojski, Gene S. Tan, Ciriyam Jayaprakash, Elena Zaslavsky, Randy A. Albrecht, Stuart C. Sealfon, Adolfo García-Sastre, Ana Fernandez-Sesma
Journal of Virology Sep 2019, 93 (20) e00559-19; DOI: 10.1128/JVI.00559-19

Influenza A virus (IAV)
Different host tissues respond during infection

“Characterizing the Different Effects of Zika Virus Infection in Placenta and Microglia Cells”
Martinez Viedma, M.P.; Pickett, B.E. Characterizing the Different Effects of Zika Virus Infection in Placenta and Microglia Cells.
Viruses 201810, 649.

Zika virus
Study the mechanisms governing the “antiviral state” (AVS) at the mucosal sites for viral defense

“IRF1 Maintains Optimal Constitutive Expression of Antiviral Gens and Regulates the Early Antiviral Response”
Panda D, Gjinaj E, Bachu M, Squire E, Novatt H, Ozato K and Rabin RL (2019) IRF1 Maintains Optimal Constitutive Expression of Antiviral Genes and Regulates the Early Antiviral Response.
Front. Immunol. 10:1019. doi: 10.3389/fimmu.2019.01019

Vesicular stomatitis virus (VSV), influenza virus

Vaccine development and evaluation

Develop a new vaccine platform

“An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies”
Behzadi, M.A.; Stein, K.R.; Bermúdez-González, M.C.; Simon, V.; Nachbagauer, R.; Tortorella, D. An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies.
Vaccines 20197, 51.

Human cytomegalovirus (CMV)e
Microneutralization assay for human in vitro platform known as MIMIC to evaluate immune response to the vaccine candidate

“A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain”
Kurt A. Swanson, Jennifer N. Rainho-Tomko, Zachary P. Williams, Lilibeth Lanza, Michael Peredelchuk, Michael Kishko, Vincent Pavot, Judith Alamares-Sapuay, Haritha Adhikarla, Sankalp Gupta, Sudha Chivukula, Scott Gallichan, Linong Zhang, Nicholas Jackson, Heesik Yoon, Darin Edwards, Chih-Jen Wei, Gary J. Nabel
Science Immunology01 May 2020

Respiratory syncytial virus (RSV)
Preclinical immunogenicity and efficacy evaluation in mice for vaccine development

“Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice”
Baldwin, W.R., Livengood, J.A., Giebler, H.A. et al. Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice.
Sci Rep 8, 16509 (2018). https://doi.org/10.1038/s41598-018-34735-7

Zika virus
Protein-based vaccine candidate evaluation

“Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus”
Mark J. Bailey, Felix Broecker, James Duehr, Fortuna Arumemi, Florian Krammer, Peter Palese, Gene S. Tan
mBio Apr 2019, 10 (2) e02861-18; DOI: 10.1128/mBio.02861-18

Zika virus

Antiviral drug screening

Identify druggable human proteins or factors as targets to screen existing pharmacological agents with antiviral activity

“A SARS-CoV-2 protein interaction map reveals targets for drug repurposing”
Gordon, D.E., Jang, G.M., Bouhaddou, M. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Nature (2020). https://doi.org/10.1038/s41586-020-2286-9

“A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals”
bioRxiv 2020.04.16.044016; doi: https://doi.org/10.1101/2020.04.16.044016

SARS-CoV-2 virus

Gene therapy, vaccine development new assays

Automate and speed up plaque assay for rAAV process development

“Integration of Fluorescence Detection and Image-Based Automated Counting Increases Speed, Sensitivity, and Robustness of Plaque Assays”
Allyson L.Masci, Emily B.Menesale, Wei-Chiang Chen, Carl Co, Xiaohui Lu, Svetlana Bergelson
https://doi.org/10.1016/j.omtm.2019.07.007
Molecular Therapy: Methods & Clinical Development Vol. 14 September 2019

HSV-1
“A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry” MERS-CoV
Develop a panel of engineered reporter influenza viruses for in-depth profiling of neutralizing antibodies using 384 well microneutralization assay
“A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies”
Adrian Creanga, Rebecca A. Gillespie, Brian E. Fisher, Sarah F. Andrews, Liam Hatch, Tyler Stephens, Yaroslav Tsybovsky, Michelle C. Crank, Adrian B. McDermott, John R. Mascola, Barney S. Graham, Masaru Kanekiyo
bioRxiv 2020.02.24.963611; doi: https://doi.org/10.1101/2020.02.24.963611 
Panel of influenza with fluorescence reporter
Monitor gene silencing induced using lentiviral vectors
“Effect of Periostin Silencing on the Autophagy of Osteoblasts”
Han Qin and Jun Cai
Cellular Reprogramming Jun 2019.122-128.http://doi.org/10.1089/cell.2018.0051
Lentiviral vector